FrancophonIA/ELRC3.0 huggingface dataset:
English: Consideration should also be given to other official guidance on the appropriate use of human hepatitis B immunoglobulin for imtramuscular use.
Estonian: Arvestada tuleks ka muid hepatiit B humaanimmunoglobuliini intramuskulaarse kasutamise kohta käivaid ametlikke juhiseid.
English: - Immunoprophylaxis of hepatitis B in haemodialysed patients:
Estonian: - Hepatiit B immunoprofülaktika hemodialüüsi läbivatel patsientidel:
English: In addition, an updated RMP should be submitted
Estonian: Lisaks tuleb uuendatud riskijuhtimise kava esitada järgmistel juhtudel:
English: ImmunoGam is a clear to slightly opalescent and colourless or pale yellow liquid.
Estonian: ImmunoGam on läbipaistev kuni kergelt opalestseeruv ja värvitu või kergelt kollakas vedelik.
English: The hepatitis B immunoglobulin administration may need to be repeated until seroconversion following vaccination
Estonian: Hepatiit B immunoglobuliini manustamist tuleb vajadusel korrata kuni vaktsineerimisjärgse serokonversiooni ilmnemiseni
English: This may result in falsely elevated glucose readings and consequently in the inappropriate administration of insulin which may result in hypoglycemia.
Estonian: See võib põhjustada ekslikke kõrgenenud glükoosinäite, mistõttu võib insuliini ebaõigest manustamisest tekkida eluohtlik hüpoglükeemia.
English: Immunoglobulin administration may interfere with the development of an immune response to live attenuated virus vaccines such as rubella, mumps, measles and varicella for a period of 3 months.
Estonian: Immunoglobuliini manustamine võib kuni kolme kuu jooksul häirida immuunsuse väljakujunemist nõrgestatud elusvaktsiini toimel selliste viiruste vastu nagu punetised, mumps, leetrid ja tuulerõuged.
English: Human hepatitis B immunoglobulin should be administrated three to four weeks after vaccination with such a live attenuated vaccine; in case administration of human hepatitis B immunoglobulin is essential within three to four weeks after vaccination, then revaccination should be performed three months after the administration of
Estonian: Juhul kui hepatiit B humaanimmunoglobuliini manustamine on kolme või nelja nädala jooksul pärast vaktsineerimist hädavajalik, tuleb kolm kuud pärast hepatiit B humaanimmunoglobuliini manustamist uuesti vaktsineerida.
English: Any unused product should be disposed of in accordance with local requirements.
Estonian: Kasutamata ravim tuleb hävitada vastavalt kohalikele seadustele.
English: Do not use solutions that are cloudy or have deposits.
Estonian: Ärge kasutage hägusaid või settega lahuseid.
English: If any uncertainty exists, the manufacturer of the testing system should be contacted to determine if the system is appropriate for use with
Estonian: Kahtluste korral võtke ühendust testimissüsteemi tootjaga veendumaks, et süsteemi sobib kasutada koos maltoosi sisaldavate süstitavate ravimitega.
English: Accordingly, when administering ImmunoGam or other parenteral maltose-containing products, the measurement of blood glucose must be done with a glucose-specific method.
Estonian: Seetõttu tuleb ImmunoGami või teiste süstitavate maltoosi sisaldavate ravimite manustamisel vereglükoosi mõõta glükoosi suhtes spetsiifiliste meetodite abil.
English: Consideration should also be given to dose and dose schedules for human hepatitis B immunoglobulin for intramuscular use recommended in other official guidance.
Estonian: Arvestada tuleks ka teistes ametlikes juhistes toodud hepatiit B humaanimmunoglobuliini intramuskulaarse kasutamise annuseid ja annustamisgraafikuid.
English: This is because ImmunoGam may interfere with the response to some attenuated vaccines, such as measles, rubella, mumps, and chicken pox.
Estonian: See on vajalik sellepärast, et ImmunoGam võib segada nõrgestatud elusvaktsiinide (näiteks leetrid, punetised, mumps ja tuulerõuged) toimet.
English: Undesirable effects reported during clinical trials with ImmunoGam, that was administered intramuscularly (injected into a muscle), were uncommon (affects 1 to 10 users in 1,000).
Estonian: Intramuskulaarselt manustatava (lihasesse süstitava) ImmunoGami kohta läbi viidud kliinilistes uuringutes täheldatud ja ImmunoGamiga seostatud kõrvaltoimed esinesid aeg-ajalt (ühel kuni kümnel patsiendil tuhandest).
English: It is strongly recommended that every time ImmunoGam is administered to a patient, the name and batch number of the medicinal product are recorded in order to maintain a link between the patient and the batch
Estonian: Et säilitada seost patsiendi ja ravimipartii vahel, on tungivalt soovitatav kirjutada igal ImmunoGami patsiendile manustamise korral üles ravimi nimi ja partii number.
English: - Prevention of hepatitis B in case of accidental exposure in non-immunised subjects: At least 500 IU, depending on the intensity of exposure, as soon as possible after exposure, and preferably
Estonian: - Hepatiit B vältimine vaktsineerimata isikute juhuslikul kokkupuutel haigustekitajatega: sõltuvalt kokkupuute intensiivsusest vähemalt 500 RÜ-d võimalikult kiiresti pärast kokkupuudet ja eelistatavalt 24-72 tunni jooksul.
English: In general for immunoglobulin products, adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Estonian: Immunoglobuliini sisaldavad ravimid võivad aeg-ajalt põhjustada selliseid kõrvaltoimeid, nagu näiteks külmavärinaid, peavalu, palavikku, oksendamist, allergilisi reaktsioone, iiveldust, liigesevalu, madalat vererõhku ja mõõdukat valu alaseljas.
English: The measures taken may be of limited value against non-enveloped viruses such as HAV and parvovirus B19.
Estonian: Kasutatavad meetmed ei pruugi olla nii tõhusad ümbriseta viiruste (nt HAV ja parvoviirus B19) puhul.
English: In case of shock, standard medical treatments for shock should be implemented.
Estonian: Šoki korral tuleb anda tavapärast meditsiinilist esmaabi selle leevendamiseks.
English: No data is available in the event of an overdose.
Estonian: Üleannustamise kohta andmed puuduvad.
English: Each ml contains 312 IU Human hepatitis B immunoglobulin, corresponding to a protein content of 30-70 mg/ml of which 96% is Immunoglobulin G (IgG).
Estonian: Iga milliliiter sisaldab 312 RÜ-d hepatiit B humaanimmunoglobuliini, mis vastab proteiinisisaldusele 30-70 mg/ml, millest 96% on immunoglobuliin G (IgG).
English: Each ml contains 312 IU Human Hepatitis B Immunoglobulin corresponding to a protein content of 30-70 mg/ml with at least 96% Immunoglobulin G (IgG).
Estonian: Iga ml sisaldab 312 RÜ-d hepatiit B humaanimmunoglobuliini, mis vastab proteiinisisaldusele 30-70 mg/ml, millest vähemalt 96% on immunoglobuliin G (IgG).
English: Patients who have an IgA deficiency may develop an allergic reaction to this medicine.
Estonian: ImmunoGam sisaldab vähesel määral IgA-d. IgA-puudulikkusega patsientidel võib selle ravimi suhtes tekkida allergiline reaktsioon.
English: It is strongly recommended that every time you receive a dose of ImmunoGam, the name and batch number of the product are recorded in your physician's notes in order to maintain a record of the batches used.
Estonian: Et säilitada kasutatud partiide nimekirja, on tungivalt soovitatav igal ImmunoGami manustamise korral arsti märkmetesse üles kirjutada toote nimi ja partii number.
English: Solutions that are cloudy or have deposits should not be used.
Estonian: Hägusaid või settega lahuseid ei tohi kasutada.
English: Prevention of hepatitis B in the newborn, of a hepatitis B virus carrier-mother, at birth or
Estonian: Hepatiit B vältimine vastsündinul, kelle ema on hepatiit B viiruse kandja, sündimisel või võimalikult ruttu pärast sündi
English: The product information of the blood glucose testing systems, including that of the test strips, should be carefully reviewed to determine if the system is appropriate for use with maltose-containing parenteral products.
Estonian: Veendumaks, et süsteemi sobib kasutada koos maltoosi sisaldavate süstitavate ravimitega, tuleb hoolikalt lugeda vereglükoosi testimise süsteemide tooteinfot, sh testribade oma.
English: The measures taken may be of limited value against non-enveloped viruses such as hepatitis A virus and parvovirus B19.
Estonian: Kasutatavad meetmed ei pruugi olla nii tõhusad ümbriseta viiruste puhul (näiteks hepatiit A viirus ja parvoviirus B19).
English: The solution should be clear to slightly opalescent and colourless or pale yellow essentially free of foreign particles.
Estonian: Lahus peaks olema läbipaistev kuni kergelt opalestseeruv ja värvitu või kergelt kollakas, võõrosakestest puhas.
English: ImmunoGam should be brought to room temperature (approximately 20°C to 25°C) before use
Estonian: Enne kasutamist tuleb ImmunoGam soojendada toatemperatuurini (ligikaudu 20°C kuni 25°C)
English: ImmunoGam should be brought to room temperature (approximately 20°C to 25°C ) before use.
Estonian: Enne kasutamist tuleb ImmunoGam soojendada toatemperatuurini (ligikaudu 20°C kuni 25°C).
English: - Newborn of a hepatitis B virus carrier-mother.
Estonian: - vastsündinud, kelle ema on hepatiit B viiruse kandja;
English: The solution should be clear to slightly opalescent and colourless or pale yellow.
Estonian: Lahus peaks olema läbipaistev kuni kergelt opalestseeruv ja värvitu või kergelt kollakas.
English: - The active substance is Human hepatitis B immunoglobulin.
Estonian: - Toimeaine on hepatiit B humaanimmunoglobuliin.
English: Prevention of hepatitis B in case of accidental
Estonian: Hepatiit B vältimine vaktsineerimata isikute juhuslikul kokkupuutel haigustekitajatega
English: oC).
Estonian: Tootja
English: EXPIRY DATE
Estonian: Häired testimisel
English: ImmunoGam is presented as a solution for injection in a glass vial.
Estonian: ImmunoGam on süstelahus klaasist viaalis.
English: No adverse events were reported in the post marketing use of ImmunoGam for Immunoprophylaxis of
Estonian: Turustamisjärgsed kogemused: andmed kõrvaltoimete kohta ImmunoGami turustamisjärgsel kasutamisel hepatiit B näidustuste immunoprofülaktikaks puuduvad.
English: BEFORE YOU RECEIVE IMMUNOGAM
Estonian: KUIDAS IMMUNOGAMI MANUSTADA
English: • CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE
Estonian: • MÜÜGILOA HOIDJALE ESITATUD HANKE- JA KASUTUSTINGIMUSED JA -PIIRANGUD Retseptiravim.
English: ImmunoGam 312 IU/ml solution for injection
Estonian: ImmunoGam 312 RÜ/ml süstelahus Hepatiit B humaanimmunoglobuliin
English: Related undesirable effects within 7 days of ImmunoGam administration, from clinical trials conducted using the intramuscular route of administration is tabulated below:
Estonian: Järgmises tabelis on toodud kõrvaltoimed, mis võivad esineda 7 päeva jooksul ImmunoGami manustamisest.
English: In case of shock, standard medical treatments for shock should be administered.
Estonian: Teave põhineb intramuskulaarset manustamisviisi hõlmavatel kliinilistel uuringutel.
English: United Kingdom Pfizer Limited
Estonian: Ühendkuningriik Pfizer Limited
English: United Kingdom Nrim Limited
Estonian: Ühendkuningriik Nrim Limited
English: Pharmatex Italia Srl Vancotex
Estonian: Pharmatex Italy Srl Vancotex
English: United Kingdom Laboratorio Reig Jofre, S.A.
Estonian: Ühendkuningriik Laboratorio Reig Jofre, S.A.
English: United Kingdom Co-Pharma Limited Vancomycin CoPharma
Estonian: Ühendkuningriik Co-Pharma Limited Vancomycin CoPharma
English: United Kingdom Sandoz Ltd
Estonian: Ühendkuningriik Sandoz Ltd
English: United Kingdom Actavis Group Ptc Ehf.
Estonian: Ühendkuningriik Actavis Group Ptc Ehf.
English: 512.6 - 520.1MG VIAL
Estonian: 512.6 - 520.1MG
English: DIRECT INTRAVENOUS INJECTION
Estonian: OTSENE INTRAVENOOSNE
English: INFUSION
Estonian: INFUSIOON
English: United Kingdom Noridem Enterprises Ltd
Estonian: Ühendkuningriik Noridem Enterprises Ltd
English: United Kingdom Teva Uk Limited Vancomycin Teva Uk VANCOMYCIN 1000MG VIAL
Estonian: Ühendkuningriik Teva Uk Limited Vancomycin Teva Uk VANCOMYCIN 1000MG VIAL
English: United Kingdom Teva Uk Limited Vancomycin Teva Uk VANCOMYCIN 500MG VIAL
Estonian: Ühendkuningriik Teva Uk Limited Vancomycin Teva Uk VANCOMYCIN 500MG VIAL
English: Sandoz Gmbh
Estonian: Sandoz Gmbh Edicin
English: United Kingdom Hikma Farmacêutica (Portugal), S.A.
Estonian: Ühendkuningriik Hikma Farmacêutica (Portugal), S.A.
English: Mylan Pharmaceuticals, S.L.
Estonian: Pharmaceuticals, S.L.
English: United Kingdom Wockhardt Uk Ltd Vancomycin Wockhardt Uk Ltd
Estonian: Ühendkuningriik Wockhardt Uk Ltd Vancomycin Wockhardt Uk Ltd
English: United Kingdom Morningside Healthcare Ltd
Estonian: Healthcare Ltd Morningside Healthcare
English: Eli Lilly Italia S.P.A. Vancocina A.P.
Estonian: Eli Lilly Italia S.P.A.
English: SOLUTION FOR INJECTION/INFUSION
Estonian: SÜSTELAHUSE PULBER/INFUSIOON
English: Hikma Italia S.P.A. Vancomicina
Estonian: Hikma Italia S.P.A.
English: Vancomycin Hydrochloride Pharmaceutical
Estonian: Vancomycin Hydrochloride Pharmaceutical Trading
English: United Kingdom Mip Pharma Gmbh Vancomycin Mip Pharma Gmbh
Estonian: Ühendkuningriik Mip Pharma Gmbh Vancomycin Mip Pharma Gmbh
English: Ratiopharm Gmbh Vancomycin
Estonian: Ratiopharm Gmbh Vancomycin Ratiopharm
English: Flynn Pharma Limited Vancocin Matrigel
Estonian: Flynn Pharma Ltd. Vancocin Matrigel
English: POWDER FOR CONCENTRATE FOR
Estonian: KONTSENTRAADI PULBER
English: United Kingdom Xellia Pharmaceuticals Aps
Estonian: Ühendkuningriik Xellia Pharmaceuticals Aps
English: CAPSULE, HARD ORAL USE
Estonian: MANUSTAMINE, SUUKAUDNE MANUSTAMINE
English: United Kingdom Flynn Pharma Limited Vancocin Matrigel
Estonian: Ühendkuningriik Flynn Pharma Ltd. Vancocin Matrigel
English: VANCOMYCIN HYDROCHLORIDE 128.15MG CAPSULE
Estonian: HYDROCHLORIDE 128.15MG CAPSULE
English: ORAL USE
Estonian: SUUKAUDNE MANUSTAMINE
English: United Kingdom Hospira Uk Ltd Vancomycin Hydrochloride
Estonian: Ühendkuningriik Hospira Uk Ltd Vancomycin Hydrochloride
English: Flynn Pharma Limited Vancocin
Estonian: Flynn Pharma Limited
English: INJECTION
Estonian: INHALATSIOON
English: United Kingdom Flynn Pharma Ltd.
Estonian: Ühendkuningriik Flynn Pharma Ltd. Vancocin
English: ORAL SOLUTION, POWDER FOR INFUSION
Estonian: SUUKAUDNE LAHUS, INFUSIOONILAHUSE PULBER
English: Flynn Pharma Ltd.
Estonian: Flynn Pharma Ltd. Vancocin
English: Vancomicina Normon VANCOMYCIN 1G VIAL POWDER FOR SOLUTION FOR
Estonian: Vancomicina Normon VANCOMYCIN 1G VIAL
English: HYDROCHLORIDE 1020MG VIAL
Estonian: VANCOMYCIN HYDROCHLORIDE 1020MG VIAL
English: Vancomicina Sala VANCOMYCIN 1G VIAL POWDER FOR SOLUTION FOR
Estonian: Vancomicina Sala VANCOMYCIN 1G VIAL
English: Vancomicina Hospira VANCOMYCIN 1G VIAL POWDER FOR SOLUTION FOR
Estonian: Vancomicina Hospira VANCOMYCIN 1G VIAL
English: Vancomicina Generis VANCOMYCIN HYDROCHLORIDE 500 mg VIAL
Estonian: Vancomycin Actavis VANCOMYCIN HYDROCHLORIDE 500MG VIAL
English: VANCOMYCIN 1G VIAL POWDER FOR
Estonian: VANCOMYCIN 1G VIAL
English: POWDER FOR ORAL INTRAVENOUS USE,
Estonian: INTRAVENOOSNE MANUSTAMINE, SUUKAUDNE
English: Trading
Estonian: SÜSTIMINE
English: Vancomycin Mylan VANCOMYCIN 1G VIAL POWDER FOR SOLUTION FOR
Estonian: Vancomycin Mylan VANCOMYCIN 1G VIAL
English: Vancomycin Norma VANCOMYCIN 500MG VIAL
Estonian: Norma Hellas S.A. Vancomycin Norma VANCOMYCIN 500MG VIAL
English: POWDER FOR
Estonian: PULBER
English: Ratiopharm HYDROCHLORIDE 512.5MG VIAL
Estonian: VANCOMYCIN HYDROCHLORIDE 512.5MG VIAL
English: Fresenius Kabi ванкомицин каби VANCOMYCIN 500MG POWDER FOR
Estonian: Fresenius Kabi Bulgaria Eood ванкомицин каби VANCOMYCIN 500MG INFUSIOONILAHUSE KONTSENTRAADI
English: The European Commission granted a marketing authorisation valid throughout the European Union for Neoclarityn on 15 January 2001.
Estonian: Euroopa Komisjon andis Neoclarityni müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. jaanuaril 2001.
English: The side effects seen in children are similar.
Estonian: Laste kõrvalnähud on samalaadsed.
English: The dose in children depends on their age.
Estonian: Laste annus sõltub vanusest.
English: Adults and adolescents can use any form of the medicine.
Estonian: Täiskasvanud ja noorukid tohivad seda ravimit kasutada mis tahes vormis.
English: The full EPAR for Neoclarityn can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Neoclarityni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Other information about Neoclarityn
Estonian: Muu teave Neoclarityni kohta
English: This is a summary of the European public assessment report (EPAR) for Neoclarityn.
Estonian: See on ravimi Neoclarityn Euroopa avaliku hindamisaruande kokkuvõte.
English: Neoclarityn has also been studied in 416 patients with urticaria.
Estonian: Neoclarityni uuriti ka 416 urtikaariaga (nõgestõvega) patsiendil.
English: Neoclarityn has been studied in a total of eight studies involving about 4,800 adult and adolescent patients with allergic rhinitis (including four studies in seasonal allergic rhinitis, and two studies in patients who also had asthma).
Estonian: Neoclarityni uuriti kokku 8 uuringus, milles osales ligikaudu 4800 täiskasvanut ja noorukit, kellel oli allergiline riniit (sh 4 uuringus uuriti hooajalist allergilist riniiti ja 2 uuringus patsiente, kellel oli ka astma).
English: In all studies, the effectiveness of Neoclarityn was compared with that of placebo (a dummy treatment).
Estonian: Kõikides uuringutes võrreldi Neoclarityni efektiivsust platseebo (näiva ravimi) efektiivsusega.
English: In adults and adolescents, the most common side effects are fatigue (tiredness; 1.2%), dry mouth (0.8%) and headache (0.6%).
Estonian: Täiskasvanute ja noorukite kõige sagedamad kõrvalnähud on väsimus (1,2%), suukuivus (0,8%) ja peavalu (0,6%).
English: For more information about treatment with Neoclarityn, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Neoclarityniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Additional studies were presented to show that the syrup, oral solution and orodispersible tablets are treated by the body in the same way as the tablets, and to show that they can be used safely in children.
Estonian: Esitati lisauuringud, mis tõendasid, et siirupi, suukaudse lahuse ja suus dispergeeruvate tablettidena manustatud ravimile reageerib organism samamoodi kui tablettidena manustatud ravimile, samuti tõendati nende ravimvormide kasutamise ohutus lastel.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Neoclarityn.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: In children less than two years of age, the most common side effects are diarrhoea (3.7%), fever (2.3%) and insomnia (difficulty sleeping; 2.3%).
Estonian: Alla 2-aastastel lastel on kõige sagedamad kõrvalnähud kõhulahtisus (3,7%), palavik (2,3%) ja unetus (2,3%).
English: Neoclarityn is a medicine containing the active substance desloratadine.
Estonian: Neoclarityn on ravim, mis sisaldab toimeainena desloratadiini.
English: The active substance in Neoclarityn, desloratadine, is an antihistamine.
Estonian: Neoclarityni toimeaine desloratadiin on antihistamiin.
English: Neoclarityn must not be used in people who are hypersensitive (allergic) to desloratadine, loratadine or any of the other ingredients.
Estonian: Neoclarityni ei tohi kasutada patsiendid, kes on desloratadiini, loratadiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: For the full list of all side effects reported with Neoclarityn, see the package leaflet.
Estonian: Neoclarityni kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: It is available as a 5 mg tablet, 2.5 mg and 5 mg orodispersible tablets (tablets that dissolve in the mouth), a 0.5 mg/ml syrup and a 0.5 mg/ml oral solution.
Estonian: Ravimit turustatakse 5 mg tabletina, 2,5 mg ja 5 mg suus dispergeeruva tabletina, 0,5 mg/ml siirupina ja 0,5 mg/ml suukaudse lahusena.
English: It works by blocking the receptors to which histamine, a substance in the body that causes allergic symptoms, normally attaches itself.
Estonian: See blokeerib retseptorid, mille külge tavaliselt kinnitub organismis allergiasümptomeid põhjustav aine histamiin.
English: Why has Neoclarityn been approved?
Estonian: Miks Neoclarityn heaks kiideti?
English: The CHMP decided that Neoclarityn's benefits are greater than its risks for the relief of symptoms associated with allergic rhinitis or urticaria and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Neoclarityni kasulikkus allergilise riniidi või urtikaaria sümptomite leevendamisel on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: What is Neoclarityn?
Estonian: Mis on Neoclarityn?
English: What is the risk associated with Neoclarityn?
Estonian: Mis riskid Neoclarityniga kaasnevad?
English: The effectiveness was measured by looking at the change in the symptoms (itching, number and size of hives, interference with sleep and daytime function) before and after six weeks of treatment.
Estonian: Ravimi efektiivsust hinnati sümptomite (sügelus, lööbenähtude arv ja suurus, une- ja ärkvelolekuaeg) muutuste põhjal enne ja pärast kuuenädalast ravi.
English: In allergic rhinitis, looking at the results of all studies taken together, two weeks of treatment with 5 mg Neoclarityn led to an average decrease in symptom score of 25 to 32%, compared with a decrease of 12 to 26% in the patients receiving placebo.
Estonian: Kõigi allergilise riniidi uuringute koondtulemus oli, et 5 mg Neoclarityni kahenädalase ravi järel muutus sümptomite punktisumma keskmiselt 25%-lt 32%-le, platseeborühmas aga 12%-lt 26%-le.
English: The effectiveness of Neoclarityn was measured by looking at the change in the symptoms (nasal discharge, itching, sneezing and congestion) before and after two or four weeks of treatment.
Estonian: Neoclarityni efektiivsust hinnati sümptomite (ninaeritised, sügelus, aevastamine ja ninakinnisus) muutuste põhjal enne ja pärast kahe- või neljanädalast ravi.
English: In the two studies in urticaria, the decrease in symptom score after six weeks of treatment with Neoclarityn was 58 and 67%, compared with 40 and 33% in placebo-treated patients.
Estonian: Urtikaaria kahes uuringus muutus Neoclarityni kuuenädalase ravi järel sümptomite punktisumma tulemuselt 58% tulemusele 67%, platseeborühmas tulemuselt 40% tulemusele 33%.
English: Neoclarityn is used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives).
Estonian: Neoclarityni kasutatakse allergilise riniidi (allergiast, nt heinapalavikust või tolmulestaallergiast põhjustatud ninaõõnepõletik) või nõgestõve (allergiast põhjustatud nahaseisund, mille sümptomite hulka kuuluvad sügelus ja nahakublad) sümptomite leevendamiseks.
English: For children from six to 11 years of age, the dose is 2.5 mg once a day, taken either as 5 ml of the syrup or oral solution, or as one 2.5 mg orodispersible tablet.
Estonian: 6-11-aastaste laste annus on 2,5 mg üks kord ööpäevas, manustatuna 5 ml siirupina või suukaudse lahusena või 2,5 mg suus dispergeeruva tabletina.
English: What benefit has Neoclarityn shown during the studies?
Estonian: Milles seisneb uuringute põhjal Neoclarityni kasulikkus?
English: For children from one to five years of age, the dose is 1.25 mg once a day, taken as 2.5 ml syrup or oral solution.
Estonian: 1-5-aastaste laste annus on 1,25 mg üks kord ööpäevas, manustatuna 2,5 ml siirupina või suukaudse lahusena.
English: How is Neoclarityn used?
Estonian: Kuidas Neoclarityni kasutatakse?
English: What is Neoclarityn used for?
Estonian: Milleks Neoclarityni kasutatakse?